Vancouver, British Columbia, September 6, 2022 – Genix Pharmaceuticals Corporation (TSX-V: GENX; OTCQB:
GENPF) (“Genix” or the “Company”) announces that the Company has received a resignation letter from its
auditor, Harbourside CPA, LLP (“Harbourside”), on August 25, 2022, with immediate effect. Harbourside has
decided to cease operations and as a result, must resign on their own initiative. Harbourside has confirmed that
there are no reportable events, “disagreements” or “unresolved issues” (as those terms are defined in National
Instrument 51-102 – Continuous Disclosure Obligations) in connection with the change of auditor. Genix is in the
process of engaging a replacement auditor for the 2022 fiscal year.
Genix Pharmaceuticals Corporation is a novel and generic ophthalmic drugs company. The Company is focused
on the research, development, manufacture, licensing, and sales of novel and innovative healthcare products. In
particular, these products include evidence-based, proprietary over-the-counter (“OTC”) nutraceuticals, and other
single molecule generic drugs that have been shown to deliver consistent and verifiable results in various
therapeutic areas. The Company will market and sell its portfolio of novel and generic ophthalmic drugs in Canada
and globally and its nutraceutical products in North America and other select countries. Genix continues to
conduct its scientific R&D of new, innovative products to support the health needs of mainstream consumers.
On Behalf of the Board of Directors,
Mr. Mahmoud Aziz, President, Director
Genix Pharmaceuticals Corporation
For more information regarding Genix Pharmaceuticals Corporation, please contact:
Kevin Bottomley, Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not
historical in nature are intended to be, and are hereby identified as, “forward‐looking statements”. Forward‐looking statements may
be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company
cautions readers that forward‐looking statements, including without limitation those relating to the Company’s future operations and
business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated
in the forward‐looking statements.